- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01663259
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients
Taking into account the excellent prognosis of patients with HPV-positive oropharyngeal cancer with < 10 pack-year smoking, the investigators hypothesize that reducing the intensity of therapy for these patients will reduce treatment sequelae, notably long-term dysphagia, without affecting their cure rates. The main Aim is to assess whether reducing treatment intensity, by replacing concurrent chemotherapy with cetuximab, will indeed achieve improved long-term toxicity.
The primary objectives include the following: to confirm that reducing treatment intensity in patients with HPV-related oropharyngeal cancer and < 10 pack-year smoking history by replacing concurrent chemotherapy with concurrent cetuximab, does not significantly increase the proportion of patients whose tumors recur, compared to our previous experience in similar patients receiving chemo-RT and to compare the toxicity in patients receiving cetuximab-RT to similar patients treated with 7 weeks of chemotherapy concurrent with RT ("standard therapy") in UMCC 2-21.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators have shown in past experience a high success in getting rid of oropharyngeal cancer (tonsil or base of tongue cancer) using chemotherapy and radiation therapy in patients who have not smoked, or only smoked a minimal amount of cigarettes or equivalent. In these patients, the cancer is thought to be caused by a virus (Human Papilloma Virus, or HPV). HPV is a virus that infects the epidermis (outermost layer of skin) and mucous membranes of humans. In general, patients with HPV-related cancer such as yours have a better prognosis compared with patients whose tumors are smoking-related. Taking into account the good prognosis, it is possible that reducing the intensity of therapy will not affect the high rate of tumor control, while reducing the side-effects of therapy. In this study, the investigators plan to reduce the intensity of treatment by replacing the currently used chemotherapy drugs with an FDA approved drug, cetuximab, which is a monoclonal antibody to a growth factor which helps cancer cells grow. By opposing the effect of the growth factor, cetuximab may help radiotherapy kill cancer cells without a lot of effect on the normal tissue. It differs from chemotherapy in its more selective activity against tumors compared to normal tissue Cetuximab has the chance to preserve the high rate of success in killing the tumor but may reduce the side effects and complications of therapy in comparison to chemotherapy drugs.
The investigators would also like to know if taking cetuximab has any effect on certain cancer-related molecules in the cancer and the normal cells inside the cheek. They would like to test this by taking a small biopsy of the tumor, as well as a swab of the inside of the cheek, before and shortly after the start of therapy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Radiation Oncology , University of Michigan Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have pathologically-confirmed, previously untreated,stage III-IV(excluding N3 or T4) squamous cell carcinoma of the oropharynx, without evidence of distant metastasis
- Pretreatment tumor biopsy with sufficient tumor for HPV or p16 analysis is required. The tumor must be HPV(+) or p16(+)
Smoking history <10 pack-year or equivalent (including cigarettes, cigars, pipes, chewing tobacco, and/or marijuana). One cannabis joint is equivalent to 5 cigarettes. (Aldington etal, Thorax 2007; 62:1058-1063). Smoking status definitions (National Health Interview Survey and Behavioral Risk Factor Surveillance System (Nelson DE etal al, Am J Pub Health 2003;93:1335):
- Smokers: smoking now every day or some days in past month
- Quitters: at least 100 cigarettes/lifetime and not smoking in the past 1-12 months
- Former smoker: at least 100 cigarettes/lifetime and not smoking >12 months
Never smokers: <100 cigarettes (or equivalent)/lifetime
- KPS > 80 (see Appendix A)
- Patients must undergo pre-treatment endoscopic tumor staging and PET-CT scanning
- Laboratory criteria:
- WBC > 3500/ul
- granulocyte > 1500/ul
- Platelet count > 100,000/ul
- Total Bilirubin < 1.5 X ULN
AST and ALT < 2.5 X ULN
- Creatinine clearance >30 cc/min
- Patients must sign study specific informed consent
- Patients must have, in the opinion of a treating physician, tumor that is accessible to biopsy in the clinic.
Exclusion Criteria:
- Prior head and neck malignancy or history of other prior non-head and neck malignancy (excluding skin cancer and early stage treated prostate cancer) within the past 3 years
- Prior head and neck radiation or chemotherapy
- Any medical or psychiatric illness, which in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment or limit compliance with study requirements
- Patients residing in prison
- Patients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cetuximab
|
Before Radiotherapy patients you will receive a single loading dose of cetuximab.
Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected.
A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached.
Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF).
Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy.
In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached.
Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Recurrence
Time Frame: 2 years
|
Number of patients whose tumors recur (includes local, regional, and distant recurrence; and second primaries). Note: Research indicates that freedom from local and regional progression (FFLRP) is a more meaningful measure. Therefore, the percentage of patients with FFLRP is included below as a Post-Hoc measure. |
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: 3 years
|
In order to evaluate the toxicity in patients receiving cetuximab-RT, adverse events were clustered into three categories: None, Mild-Moderate (grade 1 or 2), and Severe (grade 3 or 4).
Graded according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4).
|
3 years
|
Treatment Related Toxicities
Time Frame: 3 years
|
Toxicities are measured by number of participants who experience one or more types or indicator of toxicity, shown as all grades and grades 3-4.
As each participant could have multiple toxicities, the number of incidents outnumbers the number of participants.
Toxicities graded according to the CTCAE v4.
|
3 years
|
Mean Change in Tumor Epidermal Growth Factor Receptor (EGFR)
Time Frame: Day 7
|
The ratio (fold change) of tumor EGFR post/pre loading dose of cetuximab.
Reported as the mean of fold changes across all participants who had an evaluable tumor sample.
|
Day 7
|
Mean Change in Tumor Phosphorylated EGFR (pEGFR)
Time Frame: Day 7
|
The ratio (fold change) of tumor pEGFR post/pre loading dose of cetuximab.
Reported as the mean of fold changes across all participants who had an evaluable tumor sample.
|
Day 7
|
Change in Tumor EGFR Level Relative to EGFR in Normal Mucosa
Time Frame: Day 7
|
Normal mucosa EGFR was assessed for comparison with EGFR in tumor sample.
The fold change in tumor EGFR level post/pre loading dose of cetuximab, relative to fold change in normal mucosa EGFR level post/pre loading dose of cetuximab was summarized across all participants who had an evaluable tumor sample and normal mucosa sample.
The value reported is the ratio of fold change in tumor/fold change in buccal EGFR.
|
Day 7
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michelle Mierzwa, MD, University of Michigan Rogel Cancer Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMCC 2009.078
- HUM00032219 (OTHER: University of Michigan IRBMED)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingHPV Vaccine | HPVUnited States, Puerto Rico
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
-
Xijing HospitalEnrolling by invitationHPV Vaccination、HPV Related Diseases、Protective EfficacyChina
-
Global Alliance to Immunize Against AIDS Vaccine...Merck Sharp & Dohme LLCCompletedHPV-Related Cervical Carcinoma | HPV
-
Emory UniversityRecruiting
-
East Carolina UniversityRecruiting
-
University of FloridaNational Cancer Institute (NCI)Active, not recruiting
-
University of MinnesotaCompleted
-
Brigham and Women's HospitalNational Institutes of Health (NIH)Not yet recruiting
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian Health; The City College of New YorkActive, not recruitingHPV VaccinationUnited States
Clinical Trials on Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted